Quintiles.com

  • Contact quintiles

    Phone:+1 866 267 4479


    Request a Proposal

  • Therapeutic Expertise Cardiovascular

  • clinical-trials-header
  • Quintiles Clinical Trial

    The challenges of cardiovascular research are many: global scope with high enrollment, competition for investigators and patients, new regulatory requirements, growing scrutiny from payers. 

    Quintiles has clinical and operational expertise in cardiology as well as the capital required to drive your product’s success.

    Specializing in cardiovascular research to give you competitive advantage

    For truly global reach and therapeutic depth, Quintiles’ experience spans more than 300 cardiovascular studies involving more than 439,000 patients in 82 countries over the past five years. We’ve built long-term relationships with academic key opinion leaders and investigators around the globe to bring unmatched expertise to your clinical development.

    Count on Quintiles to help maximize the potential of your therapy or cardiovascular device and meet your time, quality and cost objectives. From early clinical development to global registrational and late phase studies to commercialization, we offer a comprehensive solution:

    • Protocol feasibility and site identification to ensure on-target patient enrollment 
    • Regulatory strategy and execution and quality systems 
    • Accurate safety reporting to meet stakeholder demands in the US and abroad 
    • Cardiovascular device development – from catheters to combination products such as drug-eluting stents and in-vitro diagnostics

  • Cardiovascular drug development – Innovation and Insight

  • Quintiles Clinical Trails

    Cardiotoxicity testing has become a central component of drug development and is considered right from the start of the lifecycle development process. Quintiles' CardioCheck program is designed to provide rapid insight into potential cardiotoxic influences of pharmaceutical compounds.  Read Case Study

  • Quintiles Clinical Trails

    Learn about Clinical Endpoint Committees in the independent adjudication of suspected cardiovascular events during clinical trials, and the need for their employment in clinical development programs for new antidiabetic drugs for Type 2 Diabetes Mellitus.

    Read case study